Immucillin DI4G

Immucillin DI4G is a fourth-generation derivative in the Immucillin family, designed as a transition-state analog inhibitor of human purine nucleoside phosphorylase (PNP). It is being developed primarily for topical use in combination with standard therapy (meglumine antimoniate) for the treatment of cutaneous leishmaniasis. The mechanism involves potent inhibition of PNP, an enzyme essential for purine salvage pathways in both host and parasite cells. By blocking this pathway, Immucillin DI4G induces apurinic starvation and death in susceptible parasites such as Leishmania species. The drug represents an advancement over earlier generations by optimizing binding to the PNP active site[1][3][6]. Clinical trials have evaluated its efficacy and safety as a topical agent applied directly to skin ulcers caused by Leishmania braziliensis[1][3][10].

Other names

Fourth-generation Immucillin derivativeTransition-state analog inhibitor of human purine nucleoside phosphorylase